Clinical Trials on Patients With Clinical and Environmental Risk Factors for Cancer in Belgium
Total 16 results
-
Universitaire Ziekenhuizen KU LeuvenCompletedPatients With Any Condition Who Need a PICC for IV TherapyBelgium
-
General Hospital GroeningeCompletedCognitive Impairment | Cancer Patients Eligible for a Treatment With Curative IntentBelgium
-
KU LeuvenCompletedCritically Ill Patients With a Predicted Prolonged ICU StayBelgium
-
Boston Scientific CorporationCompletedPatients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, StrokeIreland, Spain, Germany, Netherlands, France, United Kingdom, Italy, Russian Federation, Portugal, Belgium, Poland, Saudi Arabia, United Arab Emirates
-
Universitaire Ziekenhuizen KU LeuvenRecruitingNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorBelgium
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingHigh-Risk Neuroblastoma | Patient With Insufficient Response ChemoimmunotherapyFrance, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
Novartis PharmaceuticalsTerminatedIn Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung CancerUnited States, Italy, Taiwan, Belgium, Spain, Germany, Japan
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
Universitair Ziekenhuis BrusselKom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie...RecruitingGastric Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer | Locally Advanced Breast Cancer | Cancer of Pancreas | Uterine Cancer | Salivary Gland Cancer | Metastatic Breast Carcinoma | Solid Tumor With Intermediate...Belgium
-
University Hospital, GhentCentre Hospitalier Universitaire Vaudois; University Ghent; Hopital Lariboisière and other collaboratorsCompletedBreast Cancer Stage IV | Peritoneal Carcinomatosis | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Breast Cancer Stage IIIB | Breast Cancer Stage IIIc | Ovarian Cancer Stage IIIB | Stomach Cancer Stage III | Stomach Cancer Stage IV With Metastases | Pancreas Cancer, Stage III | Pancreas Cancer, Stage...Belgium
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationUnited States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IVSpain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland